



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Padnarsertib

Cat. No.:	HY-12793		
CAS No.:	1643913-93-2		
Molecular Formula:	$C_{35}H_{29}F_3N_4O_3$		
Molecular Weight:	610.63		
Target:	PAK; NAMPT		
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (163.77 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.6377 mL	8.1883 mL	16.3765 mL
		5 mM		0.3275 mL	1.6377 mL	3.2753 mL
		10 mM		0.1638 mL	0.8188 mL	1.6377 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (3.41 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (3.41 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC ₅₀ s of <100 nM and 120 nM, respectively ^{[1][2][3]} .	
IC ₅₀ & Target	PAK4 100 nM (IC ₅₀)	Nampt 120 nM (IC ₅₀)
In Vitro	Padnarsertib attenuates the PAK4/β-catenin pathway, results in NAD depletion, and attenuates viability, invasion, and	

migration in several RCC cell lines. Inhibition of NAMPT in a cell-free enzymatic assay using recombinant NAMPT shows an IC₅₀ of approximately 120 nM for Padnarsertib. Padnarsertib attenuates G2-M transit and induces apoptosis in RCC cell lines^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Padnarsertib demonstrates a decrement of xenograft growth comparable with that of Sunitinib (HY-10255A). There are minimal Padnarsertib effects on the normal human RPTECs and no apparent toxicity in vivo^[2].

Padnarsertib is currently being investigated in a phase I human clinical trial of patients with advanced solid malignancies and NHL^[2].

Padnarsertib (oral administration; 100mg/kg or 200 mg/kg; twice a day; 14 days) demonstrates a decrement of xenograft growth without no significant weight loss. 8 hours after, Padnarsertib are measured at the end of the experiment in mouse plasma and tumors with 10757 ng/mL and 10647 ng/mL, respectively^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice ^[1]
Dosage:	100mg/kg or 200 mg/kg
Administration:	Oral administration; 100mg/kg or 200 mg/kg; twice a day; 14 days
Result:	Showed a significant decrease of xenograft growth in KPT-9274 treated mouse.

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2022 Oct;9(30):e2200717.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. WO2015003166A1

[2]. Abu Aboud O, et al. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth. Mol Cancer Ther. 2016 Sep;15(9):2119-29.

[3]. Abu Aboud O, et al. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth. Mol Cancer Ther. 2016 Sep;15(9):2119-29.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA